Search Results

The ZAP™ hCG Test is an immunoassay used for the qualitative detection of human chorionic gonadotropin in human serum, plasma or whole blood and is indicated as an aid for health care professionals in the diagnosis of early pregnancy.

The ZAP™ hCG Test is a one-step immunochromatographic assay for the rapid qualitative detection of hCG in human serum, plasma or whole blood.

Here's an analysis of the provided text regarding the acceptance criteria and study for the ZAP™ hCG Test:

1. Table of Acceptance Criteria and Reported Device Performance

The document does not explicitly state formal "acceptance criteria" with numerical thresholds against which the device was measured, as might be found in a highly structured clinical trial. Instead, it describes performance characteristics that were evaluated and compared to a predicate device. The primary success metric appears to be agreement with the predicate device and satisfactory performance in key analytical functional effectiveness studies.

2. Sample Size Used for the Test Set and Data Provenance

• Test Set Sample Size:
  • Agreement with Predicate Device: 116 serum samples.
  • Blind hCG Study: Not explicitly stated, but involved "spiked whole blood."
  • For other analytical studies (interference, cross-reactivity, whole blood/plasma correlation), specific sample sizes are not provided, but they are implied through the mention of "a number of evaluation studies."
• Data Provenance: Not explicitly stated (e.g., country of origin). The studies appear to be retrospective in nature, particularly the comparison with the predicate device and the analytical evaluations using prepared samples (spiked whole blood, interfering substances). There is no mention of prospective clinical recruitment.

3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts

Not applicable in the conventional sense. For this in vitro diagnostic device, the "ground truth" for the test set was established using:

• The results of a legally marketed predicate device (ICON® II HCG ImmunoConcentration Assay).
• A quantitative reference assay (Beckman Access® Total β-hCG assay) for discrepant samples.
• Laboratory measurements of known concentrations of interfering substances, cross-reactants, and spiked hCG levels.

There were no human experts establishing ground truth through interpretation for the performance studies described.

4. Adjudication Method for the Test Set

Not applicable for this type of in vitro diagnostic device study. Adjudication methods (like 2+1, 3+1) are typically used for studies where human interpretation of medical images or clinical cases forms the basis of ground truth, and discrepancies between readers need to be resolved. Here, the ground truth was based on instrument readings and reference assays.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance?

No, an MRMC comparative effectiveness study was not done. This device is an immunoassay for rapid qualitative detection of hCG, not an AI-assisted diagnostic tool that would be used by human readers in the interpretation of complex medical data. Therefore, the concept of human readers improving with AI assistance does not apply.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done

Yes, the studies described are essentially standalone performance evaluations of the ZAP™ hCG Test as an algorithm/device only. The device is intended to provide a direct qualitative result (positive/negative) without requiring additional human interpretation of the result strip, beyond reading the control and test bands. The "blind hCG study using spiked whole blood and involving three health care sites" further supports this, as it evaluates the device's output accuracy in a practical setting without human interpretive variability being the primary focus.

7. The Type of Ground Truth Used

The ground truth used was a combination of:

• Predicate Device Results: The established performance of a legally marketed, substantially equivalent device (ICON® II HCG ImmunoConcentration Assay).
• Quantitative Reference Assay: The Beckman Access® Total β-hCG assay was used to resolve discrepancies with the predicate device, providing a quantitative "true" value for those samples.
• Known Concentrations: For interference and cross-reactivity studies, the ground truth was known concentrations of substances deliberately added or tested against.
• Spiked Samples: For the blind study, samples were "spiked" with known concentrations of hCG to establish a clear ground truth.

8. The Sample Size for the Training Set

Not applicable. The ZAP™ hCG Test is an immunoassay kit, not a machine learning or AI algorithm that requires a "training set" in the computational sense. The device's performance is determined by its biochemical reagents and physical design, which are developed and validated through laboratory testing and manufacturing controls.

9. How the Ground Truth for the Training Set Was Established

As explained above, there is no "training set" for this type of device. The "ground truth" used during the development and validation of the assay (analogous to training/testing in ML) would involve careful preparation of samples with known hCG concentrations, interfering substances, and cross-reactants, followed by analytical testing to optimize the assay's sensitivity, specificity, and robustness.

Ask a specific question about this device